Showing 1,661 - 1,680 results of 17,945 for search 'significant ((((((gap decrease) OR (greatest decrease))) OR (nn decrease))) OR (a decrease))', query time: 0.63s Refine Results
  1. 1661

    Cardiomyocyte apoptosis rate in the Sham group. by Qingqing Hao (5464070)

    Published 2024
    “…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
  2. 1662

    Cardiomyocyte apoptosis rate in the three groups. by Qingqing Hao (5464070)

    Published 2024
    “…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
  3. 1663

    Apoptosis ratio in three groups. by Qingqing Hao (5464070)

    Published 2024
    “…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
  4. 1664

    S1 File - by Qingqing Hao (5464070)

    Published 2024
    “…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
  5. 1665

    Cardiomyocyte apoptosis rate in the HF group. by Qingqing Hao (5464070)

    Published 2024
    “…</p><p>Results</p><p>1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. …”
  6. 1666
  7. 1667

    Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation by Huang-Ju Tu (630766)

    Published 2024
    “…Although the development of DYRK1A inhibitors has significantly advanced in recent years, the selectivity of these drugs remains a critical challenge, potentially impeding further progress. …”
  8. 1668
  9. 1669
  10. 1670
  11. 1671
  12. 1672
  13. 1673
  14. 1674
  15. 1675
  16. 1676
  17. 1677
  18. 1678
  19. 1679
  20. 1680